Anixa is focused on the treatment and prevention of cancer and infectious diseases.

Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology and infectious disease.  Anixa’s oncology programs are using the body’s immune system to take multiple approaches in fighting cancer—developing treatments and vaccines.  Anixa’s infectious disease program consists of a treatment for COVID-19 focused on inhibiting certain protein function necessary for viral replication.


Therapeutics

CAR-T

We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.

COVID-19

We are developing a treatment for COVID-19 that is designed to inhibit protein function necessary for replication of SARS-CoV-2, the virus causing the disease.

Vaccines

Breast Cancer Vaccine

We are developing a revolutionary breast cancer vaccine technology focused on treating as well as preventing triple negative breast cancer (TNBC), the most lethal form of the disease.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences Breast Cancer Vaccine Technology Nearing FDA Submission

Read More...

Anixa Biosciences Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

Read More...

Anixa Biosciences' CAR-T Cancer Therapy Receives Intention to Grant Notice from the European Patent Office

Read More...

Stock Data

View Investors Relations
Nasdaq: ANIX
Price
Change